Alpha 2.0
Login Register
» Authors » T Challoner

T Challoner

Explore the profile of T Challoner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 73
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
C Briggs
M W Rampling
D Z Reinstein
D J Thomas
M Vourvachis
J Skillman
J A Green
R M Charlton
D Cunningham
R Touquet
Published In
Cancer Chemother Pharmacol
Br J Haematol
Br J Ophthalmol
Lancet
Clin Exp Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
From chaos to a new norm: The Birmingham experience of restructuring the largest plastics department in the UK in response to the COVID-19 pandemic
Leng C, Challoner T, Hausien O, Filobbos G, Baden J
J Plast Reconstr Aesthet Surg . 2020 Oct; 73(12):2136-2141. PMID: 33039307
The coronavirus disease 2019 (COVID-19) pandemic presented unprecedented challenges for healthcare systems worldwide. The Queen Elizabeth Hospital, Birmingham, has one of the largest burns, hands and plastics department in the...
2.
Oncoplastic techniques: Attitudes and changing practice amongst breast and plastic surgeons in Great Britain
Challoner T, Skillman J, Wallis K, Vourvachis M, Whisker L, Hardwicke J
Breast . 2017 May; 34:58-64. PMID: 28505558
Purpose: The availability, acceptability and practice of oncoplastic surgery has increased over the last 5 years. This study aims to describe how the breast and plastic surgical workforce has adapted...
3.
'Correctable undetected visual acuity deficit' in patients aged 65 and over attending an accident and emergency department
Reinstein D, Dorward N, Wormald R, Graham A, OConnor I, Charlton R, et al.
Br J Ophthalmol . 1993 May; 77(5):293-6. PMID: 8318466
The rate of occurrence of correctable undetected visual acuity deficit (CUVAD) in a population of patients aged 65 and over was investigated, using a pinhole screening method, to compare the...
4.
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting
Green J, Watkin S, Hammond P, Griggs J, Challoner T
Cancer Chemother Pharmacol . 1989 Jan; 24(2):137-9. PMID: 2525078
The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide. At a dose of 4 mg q 6 h, GR38032F was...
5.
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting
de Haan L, de Mulder P, Beex L, Debruyne F, Challoner T, De Pauw B
Eur J Cancer Clin Oncol . 1988 Aug; 24(8):1383-4. PMID: 2972545
No abstract available.
6.
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist
Cunningham D, Hawthorn J, Pople A, Gazet J, Ford H, Challoner T, et al.
Lancet . 1987 Jun; 1(8548):1461-3. PMID: 2885454
15 patients receiving cytotoxic drugs (other than cisplatin) that had previously produced nausea and vomiting refractory to first-line antiemetics were given a selective 5-HT3 receptor antagonist (GR38032F), 4 mg intravenously...
7.
A study of the haematological and haemorheological consequences of venesection
Challoner T, Briggs C, Rampling M, Thomas D
Br J Haematol . 1986 Apr; 62(4):671-8. PMID: 3964560
A study has been made of a number of haematological and haemorheological factors following venesection therapy. Haematocrit was very effectively reduced by the venesection regimen and led to a fall...
8.
Absence of pruritus in iron deficiency following venesection
Tucker W, Briggs C, Challoner T
Clin Exp Dermatol . 1984 Mar; 9(2):186-9. PMID: 6713720
No abstract available.
9.
A theoretical analysis of the effects of varying fibrinogen concentration and haematocrit on the flow characteristics of blood in cylindrical tubes
Rampling M, Challoner T
Biorheology . 1983 Jan; 20(2):141-52. PMID: 6871430
The viscosity: shear rate relationship of whole blood is shown to be described to a good approximation by a bi-linear plot on log: log axes. This has allowed an analytical...